Case Study
Health & Safety

Demonstrating Commitment to the Responsible Manufacture of Antibiotics

GSK Worthing: First UK site with BSI Kitemark™ for Minimized Risk of AMR in antibiotics manufacturing.

Testimonial

“We believe that by taking these steps towards responsible antibiotic manufacturing, we can contribute to getting ahead of AMR.”

Lorraine Cancro Senior Director - Environmental Compliance and Remediation, GSK

About GSK

A global biopharma company committed to getting ahead of AMR

GSK is a company focused on uniting science, technology, and talent to get ahead of disease and positively impact the health of billions of people.

The company has set ambitious goals for both climate and nature, including a commitment to stay below Predicted No-Effect Concentration levels as defined by the AMR Industry Alliance and API Wastewater discharge limits.

The Challenge

Ensuring API emissions from manufacturing are kept below levels that negatively impact human health or the environment

According to the World Health Organization, antimicrobial resistance (AMR) is one of the top 10 threats to global public health, and is expected to get worse unless action is taken.

A driving cause of AMR is manufacturing waste from the production of antibiotics being released into the environment, for example through wastewater. While GSK had a formalized programme in place to review its internal and manufacturing supply chains to minimize risk of AMR, their achievement of BSI Kitemark certification takes this one step further, independently certifying GSK’s responsible manufacturing practices and commitment to protecting public health and the environment.

The Solution

Demonstrating transparency, accountability and a commitment to addressing the global challenge of AMR

GSK sought to update and enhance its existing AMR programme and documentation procedures in order to gain the internationally recognized BSI Kitemark for Minimized Risk of Antimicrobial Resistance.

Achieving Kitemark certification involved evaluating the manufacturing processes of seven antibiotic products at the GSK Worthing site. On-site inspection of manufacturing operations was conducted by BSI auditors,including reviews of the wastewater treatment operations, storage areas, and interviews with key site team members. As part of its efforts to combat AMR and positively impact the health of people and the planet, GSK has committed to certification at all their antibiotic manufacturing sites around the world by 2026.

Go to certification

The Benefits

How BSI Kitemark certification at its Worthing manufacturing site is helping GSK to address AMR and achieve its environmental management goals:

Assurance that the antibiotics manufacturing process meets the highest international standard.
Demonstrates its commitment to addressing AMR and minimizing antimicrobial waste in the environment.
Ensures waste streams containing APIs and drug products are suitably controlled during manufacturing.
Helps protect the efficacy of antibiotics in fighting diseases.
Validates compliance with the AMR Industry Alliance’s Antibiotic Manufacturing standard.
BSI Kitemark certification further assures healthcare procurers, investors, and customers.

Commitment to AMR research

GSK is playing a leading role in the fight against AMR. Key figures include:

12

R&D projects targeting pathogens deemed ‘critical’ or ‘urgent’ by WHO and US CDC.
1st

in more than 75 countries worldwide.
1st

in the Access to Medicine Foundation’s AMR Benchmark innovation category.
£45 million

Pledged to the Fleming Initiative, to develop new AMR interventions.
22

Years of running the Survey of Antibiotic Resistance, a multinational surveillance programme.
70

Years of expertise in infectious disease R&D.

“Achieving this BSI Kitemark certification, we show our commitment to addressing AMR and minimising the risk of antimicrobial waste in the environment.”

Lorraine Cancro Senior Director - Environmental Compliance and Remediation, GSK.

Why BSI

Working in partnership for a healthier world

This Kitemark has been developed together with the AMR Industry Alliance (AMRIA), and others, to bring trust, evidence, and supply chain visibility.

Achieving certification through the BSI Kitemark™ for Minimized Risk of AMR Certification addresses a WHO global health threat, assures stakeholders, and helps protect antibiotic efficacy for future generations.

Contact Us

Addressing antimicrobial resistance together

Build trust and confidence with the BSI Kitemark™ for minimized risk of antimicrobial resistance.

Get in touch

Insights & Media

Insights from our Health, Safety and Well-being experts

Get Insights & Media

Case Study

Consumer Council NI The Kitemark™ for inclusive service

Read the Case Study

Case Study

Committed to Supporting Vulnerable Customers

Read the Case Study

Case Study

Santander and the BSI™ Kitemark for Inclusive Service

Read the Case Study